Arix Bioscience
plc
Notice of
Results
LONDON, 20 March 2019: Arix Bioscience plc (LSE: ARIX), a
global healthcare and life science company supporting medical
innovation, will announce its annual results for the year ended
31 December 2018 on Thursday,
28 March 2019.
Joe Anderson, CEO and
James Rawlingson, CFO, will host a
breakfast briefing and call for analysts at 09:30 GMT on the day of the results at Stifel,
150 Cheapside, London, EC2V 6ET.
Details of the webcast will be available on request. The webcast
will be recorded and a replay will be available on the company
website.
– ENDS –
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor
Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur
+44 (0) 203 950 9144
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science
company supporting medical innovation. Headquartered in
London and with an office in
New York, Arix Bioscience sources,
finances and builds world class healthcare and life science
businesses addressing medical innovation at all stages of
development. Operations are supported by privileged access to
breakthrough academic science and strategic relationships with
leading research accelerators and global pharmaceutical
companies.
Arix Bioscience plc is listed on the Main Market of the London
Stock Exchange. For further information, please visit
www.arixbioscience.com